Berkshire Hathaway, Cisco And A Health Care Stock: CNBC’s ‘Final Trades’
CNBC's Final Trades spotlight Berkshire Hathaway, Cisco and Eli Lilly, citing targets, raised guidance and Lilly's $1.5B Calytrix deal.
Last updated: 2026-11-17 22:43:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Eli Lilly & Co. (LLY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $1,415.14, with a market capitalization of $1.29T and a P/E ratio of 46.24. Over the past 52 weeks, its price has ranged from $850.51 to $1,475.25. This page covers its latest market performance, valuation, price trends and company information.
$1.29T | |
$1,416.00 | |
$1,439.03 | |
$1,402.34 | |
$1,431.67 | |
1.95M | |
2.60M | |
46.24 | |
$1,475.25 | |
$850.51 | |
0.47% | |
12-31 |
Eli Lilly & Co. (LLY) is trading at $1,412.49 in after-hours trading as of 2026-11-17 22:26:45, down 0.19% ($2.64) from the regular-session close of $1,415.14.
After-hours trading shows how investors are pricing LLY after the regular session closes. The current after-hours price is near the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Eli Lilly & Co. (LLY) moved from $1,354.00 to $1,415.14, representing a gain of 4.52% ($61.14).
The stock traded between $1,333.22 and $1,475.25 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 2.92 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.4%
LLY is currently trading at $1,415.14, placing it 90.4% of the way from its 52-week low of $850.51 to its 52-week high of $1,475.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 50,000 |
| CEO | David A. Ricks |
| Founded | 1876 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Eli Lilly & Co.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 13, 2026 |
| Payment Date | Dec 10, 2026 |
| Dividend Per Share | $1.73 |
Latest news related to Eli Lilly & Co. and LLY stock.
CNBC's Final Trades spotlight Berkshire Hathaway, Cisco and Eli Lilly, citing targets, raised guidance and Lilly's $1.5B Calytrix deal.
Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial (evERA)1In
Ziphius, a biotechnology company specializing in self-amplifying RNA (saRNA), announced the appointment of Antoon Loomans to its Board of Directors. Loomans, a veteran vaccine industry executive with 30 years of experience including 27 years at GSK and recent role at VaxCo (acquired by Eli Lilly for $1.55B), will lead commercial development in the US focusing on strategic partnerships and licensing. The appointment comes as Ziphius advances its lead Chlamydia trachomatis vaccine candidate toward clinical trials and conducts a €30 million fundraising round.
Four sectors are higher and seven are lower in Monday’s regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than widely separated, with the top three staying within a narrow range of one another.
Eligible investors can buy real shares of Eli Lilly & Co. (LLY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LLY, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LLY shares and USD.
LLY Shares to USD
1.00 LLY shares = 1,415.138 USD
Calculations are estimates based on the latest available price and are for reference only.